Veru (VERU) Ending Cash Position: $23.88 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VERU Veru Inc VERU
21 GF Score
Price $2.74
! 3 Warning Signs
View Full Analysis

What is Veru Ending Cash Position?

Veru VERU +1.49% 21 Ending Cash Position is $23.88 Mil as of Jun. 2026. GuruFocus rates VERU with a GF Score™ of 21/100. The stock has 3 warning signs investors should review.

Veru's Ending Cash Position for the quarter that ended in Jun. 2026 was $23.88 Mil.

Veru's quarterly Ending Cash Position declined from Dec. 2025 ($32.99 Mil) to Mar. 2026 ($27.60 Mil) and declined from Mar. 2026 ($27.60 Mil) to Jun. 2026 ($23.88 Mil).

Veru's annual Ending Cash Position increased from Sep. 2023 ($9.63 Mil) to Sep. 2024 ($24.92 Mil) but then declined from Sep. 2024 ($24.92 Mil) to Sep. 2025 ($15.80 Mil).

Veru Ending Cash Position Related Terms

Veru Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Veru's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veru Ending Cash Position Chart

Veru Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 122.36 80.19 9.63 24.92 15.80

Veru Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.01 15.80 32.99 27.60 23.88
VERU
21GF Score
Veru Inc VERU
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veru Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Veru's Ending Cash Position for the fiscal year that ended in Sep. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=24.917+-9.122
=15.80

Veru's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=27.597+-3.717
=23.88

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $23.88 Mil mean?
Veru (VERU) has a Ending Cash Position of $23.88 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Veru and its competitors.
Is Veru's Ending Cash Position too high?
Veru's current Ending Cash Position is $23.88 Mil. Overall, Veru has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Veru's Ending Cash Position compare to NTRB and LTRN?
Veru's Ending Cash Position of $23.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Veru and its competitors. Veru's current Ending Cash Position is $23.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veru stock overvalued right now?
Veru (VERU) has a current Ending Cash Position of $23.88 Mil. The current Ending Cash Position is $23.88 Mil. Veru's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Veru (VERU), the current Ending Cash Position is $23.88 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veru Business Description

Address 2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
21GF Score

Get the complete analysis for VERU

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.74
Price